...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Reports of Exempt Distribution
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Yes, pretty much all of them, with the odd exception.

One in Jan 2023 (part of a group) for 6,600 common shares @ $1.34 plus share purchase warrants exercise price of $1.34 expiry date 2023-11-14.

 

Koo

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply